Company intelligence
GoCART
Chimerous Antigen Receptor based cell therapy - with precision and adaptability.
Pharmaceutical Manufacturing
3 employees
Founded 2025
1 public signals
About GoCART
A Platform for CAR T-cell therapy that includes the critical new safety-feature of the "AND"-Gate. With this mechanism, a wide range of previously "undruggable" antigen targets become safe and therefor "druggable", giving more targeted options to existing CAR T-cell therapies, and allows targeted treatment of entirely new tumor types.
Verified activity
Signals from GoCART
1 published signal